Piper Sandler Maintains Turnstone Biologics(TSBX.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst Joseph Catanzaro maintains $Turnstone Biologics(TSBX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 3
Piper Sandler Sticks to Its Buy Rating for Turnstone Biologics Corp. (TSBX)
12 Health Care Stocks Moving In Monday's After-Market Session
GainersLarimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock ro
Leerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)
Turnstone Biologics | 10-Q: Quarterly report
Turnstone Biologics 1Q Loss/Shr 85c >TSBX
Turnstone Biologics 1Q Loss/Shr 85c >TSBX
Turnstone Biologics Q1 EPS $(0.85) Misses $(0.78) Estimate
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.78) by 8.97 percent.
Press Release: Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or th
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to tr
Turnstone Biologics Appoints William Waddill to Its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
Turnstone Biologics GAAP EPS of -$0.73 Beats by $0.25
Turnstone Biologics Q4 EPS $(0.73) Beats $(0.86) Estimate
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.86) by 15.12 percent.
Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Turnstone Biologics: Lead Program, TIDAL-01, Advancing in Phase 1 Trials With Initial Clinical Data Expected in Mid-2024 >TSBX
Turnstone Biologics 4Q Loss/Shr 73c >TSBX
Turnstone Biologics 4Q Loss/Shr 73c >TSBX
Turnstone Biologics Expects Cash, Cash Equivalents and Short-Term Investments Will Be Sufficient to Fund Ops Into 2Q of 2025 >TSBX
Turnstone Biologics Expects Cash, Cash Equivalents and Short-Term Investments Will Be Sufficient to Fund Ops Into 2Q of 2025 >TSBX
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersEtao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's market cap stands at $51.1 million. Taysha Gene Therapies (NASDAQ:TSHA) shares
12 Health Care Stocks Moving In Friday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of their outstanding shares is at $40.4 million. Ainos (NASDAQ:AIMD) sto
Turnstone Biologics Updates Presentation for Health Care Conference
Turnstone Biologics (NASDAQ:TSBX) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the
Turnstone Biologics to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
No Data